Artificial Intelligence
Clinical Highlights: 15th Annual CMHC Live Online
Boca Raton, FL, Oct. 29, 2020 (GLOBE NEWSWIRE) — The 15th Annual CMHC Live Online concluded on Saturday, October 24th. For the first time in its history, the event was delivered entirely online to practitioners across the nation. Through an innovative and user-friendly virtual platform participants were able to interact with faculty members, participate in audience polls, and more, all from the setting of their own choosing. Chaired by an esteemed panel of expert faculty members Robert H. Eckel, MD; Christie M. Ballantyne, MD; George L. Bakris, MD; Anne L. Peters, MD; Deepak L. Bhatt, MD, MPH; Keith C. Ferdinand, MD; Clyde W. Yancy, MD, MSc, MACP; and Pamela B. Morris, MD, the conference provided actionable insights on late-breaking research, advanced clinical approaches to cardiometabolic challenges, and practical strategies to tackle inequity in healthcare.
Impact of Ethnicity and Race in Cardiometabolic Health: Implications for Risk Assessment and Management
Despite therapeutic advances, the burden of cardiovascular disease (CVD), diabetes, atherosclerosis, and several cardiometabolic risk factors remains high in certain racial and ethnic minorities, including in African Americans and Latinos. Significant disparities in CVD morbidity and mortality persist, and across several outcomes and risk factors, African Americans have sub-optimal cardiovascular health. This includes a higher burden of coronary heart disease, heart failure, stroke, and traditional CVD risk factors, such as hypertension, diabetes, lipid disorders, and obesity. Additionally, Hispanic adults are more likely than non-Hispanic adults to be diagnosed with diabetes, as well as at a higher risk for significant morbidity and mortality due to diabetes, including progression to end-stage renal disease, visual impairment, and hospitalizations.
These topics were covered extensively during the pre-conference, chaired by Keith C. Ferdinand, MD, a nationally and internationally recognized cardiologist that has dedicated his career to improving patient care in racial and ethnic minorities. During his opening talk, Dr. Ferdinand mentioned that “cardiometabolic and CVD disparities by race/ethnicity, geography, and socioeconomic status exist, are sizeable, multifactorial, persistent, rarely due to genetics, and are unacceptable.”
Participants then engaged in lectures and discussions on issues such as counseling patients living in food deserts, combination medications in racially marginalized groups, navigating healthcare costs, culturally informed treatment strategies, and more. Led by a panel of clinical leaders at the intersection of race and cardiometabolic care, this offering served to help participants build a practical strategy to effectively navigate the pervasive challenges of inequity in healthcare.
Keynote: Evolving Paradigms in Cardiovascular Research and Care: Reflections and Perspectives
The keynote address was delivered by Eugene Braunwald, MD, a world-renowned cardiologist and a pioneer researcher, physician, and educator in cardiovascular medicine, considered by most to be the preeminent cardiologist of our time. During his keynote presentation, Dr. Braunwald overviewed the remarkable progress that has been achieved in preventive cardiology in just the last two decades, highlighting the role of genetics, artificial intelligence and machine learning, and groundbreaking therapeutics, including PCSK9 inhibitors and SGLT-2 inhibitors. In reviewing the initially surprising results with SGLT-2 inhibitors in cardiorenal risk, he mentioned that they have contributed to three significant paradigm shifts: they provide effective management of cardiac and renal dysfunction in patients with type 2 diabetes, improve the management of heart failure with reduced ejection fraction in patients without diabetes, and are renoprotective in patients with chronic kidney disease with and without type 2 diabetes. Dr. Braunwald concluded that care for patients with cardiovascular disease or risk has been greatly improved due to these advances, and highlighted that much still remains to be done going forward.
Hypertension, Chronic Kidney Disease, and Heart Failure Management
Kicking off the session, CMHC Chair George Bakris, MD discussed how to understand signals from the kidney when blood pressure is rapidly and aggressively controlled. In the setting of controlled blood pressure, or when BP numbers are at goal, interpretation of kidney function, including the estimated glomerular filtration rate (eGFR), albuminuria, creatinine, and potassium levels, is really important to understand in order to decrease overall cardio-renal risk, Dr. Bakris mentioned during his talk. The very important (but often neglected) role of sleep disorders in hypertension was reviewed by Virend Somers, MD, Professor at the Mayo Clinic—who gave the audience practical tips on the association of sleep disorders and hypertension, and how adequate sleeping patterns can improve blood pressure. Dr. Somers concluded by inviting the audience to participate in a CMHC masterclass focused entirely on these issues, “The Intersection of Cardiometabolic Health and Sleep Disorders”, taking place live online on March 27, 2021.
During the primetime symposium “Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches” experts Rajiv Agarwal, MD, George Bakris, MD, and Janet McGill, MD, discussed the underlying pathophysiology of DKD, how to identify patients at-risk for DKD progression, and the emerging role of non-steroidal mineralocorticoid receptor antagonists (MRAs) in DKD treatment. Clyde Yancy, MD, CMHC’s Senior Planning Committee member and Professor of Medicine at Northwestern University in Chicago, overviewed the landscape with transthyretin cardiac amyloydosis (ATTR-CM). Dr. Yancy mentioned that ATTR-CM is an underestimated cause of heart failure, and that low awareness and limited therapeutic options are significant barriers to optimal care. However, he mentioned, several therapies have been approved or are in clinical development for ATTR-CM and this condition is becoming more relevant to the practice of cardiology. The day concluded with a series of challenging cardio-renal cases to put into perspective these advances.
Dyslipidemia, Atherosclerosis, and Thrombosis
The evolving lipid targets and residual ASCVD risk beyond LDL-C was a significant focus of this session, chaired by CMHC Chair Christie Ballantyne, MD. In his talk “Beyond LDL-C: targeting inflammation to reduce cardiovascular risk”, Paul M. Ridker, MD, MPH, Professor of Medicine at the Harvard Medical School, mentioned the important role of inflammation in the development, progression, and prognosis of atherosclerosis. Patrick Moriarty, MD, Professor of Internal Medicine at the University of Kansas Medical Center in Kansas City, Kansas, overviewed the role of elevated lipoprotein a, Lp(a), and concluded that it is an independent risk factor for ASCVD that deserves appropriate screening and treatment.
The primetime symposium, “The Evolving Landscape of LDL-C Reduction: Novel Therapies and Approaches”, with Christie Ballantyne, MD, Salim Virani, MD, and Pam Taub, MD, discussed clinical inertia with LDL-C lowering, current guidelines, and the evidence and role for newer and emerging agents, including bempedoic acid and inclisiran, in addressing current gaps and needs with LDL-C lowering. The session concluded with a panel discussion of challenging cases, including severe hypertriglyceridemia, residual ASCVD risk & inflammation, elevated Lp(a), and complex primary ASCVD prevention.
Diabetes Management
C. Ronald Kahn, MD, Professor of Medicine at Harvard Medical School in Boston, MA, and prominent physician-researcher, kicked off the session with his talk titled “Insulin resistance: a 2020 update.” In his talk, Dr. Kahn mentioned that Insulin resistance is a key factor that underlines obesity, type 2 diabetes, and overall cardiometabolic risk, and concluded that “understanding what creates this multi-dimensional signaling defect should define a new approach to the therapy of type 2 diabetes.”
The primetime symposium “Preventing Cardiovascular Events in High-Risk Diabetes Patients with CAD: New Insights and Developments” explored unique issues in antithrombotic and antiplatelet therapy in diabetes patients, a key component to reduce the risk of adverse events. During this symposium, Deepak Bhatt, MD, Lawrence Leiter, MD, and Prof. Philippe Steg discussed the role of more aggressive and specific antithrombotic agents in this setting, as outlined by recent clinical trials, as well illustrated these advanced with the help of a complex patient case that took into account how to optimize lipid, glycemic, and antithrombotic and antiplatelet therapy in patients with type 2 diabetes. The session continued with a talk by Kathleen Dungan, MD, Associate Professor of Medicine at the Ohio State University in Columbus, OH, which explored new emerging therapies in the management of type 2 diabetes. One of the emerging approaches, Dr. Dungan mentioned, is the development of dual and triple peptide agents, including GLP-1/GIP agonists, novel GIP agonists, GLP-1/glucagon receptor dual agonists, and GLP-1/GIP/glucagon triagonists. In conclusion, she mentioned that “combination therapy has the potential to improve glycemic control, can overcome clinical inertia while also displaying synergistic effects.” The challenging issue of glycemic targets and reconciling them across different guidelines was overviewed by Athena Philis-Tsimikas, MD, Corporate Vice-President of Scripps Research Translational Institute. The session ended with a lively primetime symposium on the management of postprandial glucose control, which included CMHC Chair Anne L. Peters, MD, Irl Hirsch, MD, and Athena Philis-Tsimikas, MD.
Obesity and Lifestyle
Holly R Wyatt, MD, Professor and Vice Chair for Clinical Programs at the University of Alabama Birmingham, discussed challenges and solutions that clinicians face when addressing lifestyle approaches to weight reduction. Dr. Wyatt mentioned that we should be focusing more on weight maintenance than weight loss with our patients, and encouraged clinicians to write “exercise prescriptions” or refer to appropriate specialists. Alice Lichtenstein, D.Sc., Professor of Nutrition Science and Tufts University in Boston, MA, put into perspective the confusing evidence that exists about nutrition and cardiometabolic health and synthesized key messages that every clinician can take back to their practice to address nutrition with their patients—focusing on plant-sourced diets reach in vegetables, fruits, beans, and whole grains. The topics of nutrition and culinary medicine, including practical tips for meal preparation, will also be addressed in depth in the upcoming CMHC masterclass “Nutrition for the cardiometabolic patient: practical strategies to improve outcomes”, which will take place live online on March 4-5 of 2021.
The increasing prevalence of obesity and its manifestation as excess fat in the liver has given rise to a growing epidemic of fatty liver and its more severe form, non-alcoholic steatohepatitis (NASH). In his talk “NASH in a Dash”, Christos Mantzoros, MD, Professor of Medicine at Harvard Medical School, gave an overview of the epidemiology and burden of NASH, current and emerging approaches to evaluation and diagnosis, as well as what can be done now to treat NASH and what we should look forward to the near future as results about the several investigational therapies become available. Dr. Mantzoros invited interested participants to attend the upcoming CMHC masterclass that he is chairing, “Addressing the NAFLD/NASH epidemic: advances in pathophysiology, diagnosis, and management”, taking place live online on January 8-9 of 2021. The rest of the sessions included important talks on the role of metabolic surgery in decreasing overall metabolic risk, the obesity paradox, and how to incorporate and bill for behavioral therapy in obesity management, and the session was concluded with a lively panel discussion with experts Robert H. Eckel, MD, Louis J. Aronne, MD, David E. Cummings, MD, Carl J. Lavie, MD, Alice H. Lichtenstein, D.Sc., Christos S. Mantzoros, MD, DSc, and Holly R. Wyatt, MD.
Conclusion
Developed and led by the foremost clinicians, researchers, and industry thought leaders, the 15th Annual Cardiometabolic Health Congress delivered top-tier clinical perspectives from a myriad of specialties. Designed in direct response to the real-world clinical needs of active cardiometabolic practitioners and patients of all backgrounds, this cutting-edge event disseminated the latest science and clinically equitable strategies in cardiometabolic medicine available. If you are interested in learning more about these challenges, we recommend that you attend the upcoming masterclass, “Who best to stem the cardiometabolic tsunami: cardiology, endocrinology, and primary care,” chaired by Keith C. Ferdinand, MD, which will explore unique issues in the multidisciplinary management of cardiometabolic disease and will be held live online on November 19-20, 2020.
Amanda Jamrogiewicz Cardiometabolic Health Congress 561-997-0112 [email protected]
Artificial Intelligence
Astro, Malaysia’s Largest Broadcaster Selects Amagi and AWS to transition Playout Services to the Cloud
KUALA LUMPUR, Malaysia, May 29, 2024 /PRNewswire/ — Amagi, the leader in cloud-based SaaS technology for broadcast and connected TV (CTV), deployed on Amazon Web Services (AWS), today announced its partnership with Malaysia’s leading media and entertainment company – Astro Malaysia Holdings Berhad (Astro).
Astro, Malaysia’s leading content and entertainment company, in partnership with Amagi, is modernizing systems and infrastructure for the playout and origination of its existing Linear Channels and Playout Disaster Recovery capabilities and transitioning them to AWS, the world’s most comprehensive and broadly adopted cloud. This marks a milestone in ASEAN’s broadcast industry. The Amagi playout deployment will help Astro optimize its media operations, enhance business agility, increase service resilience, and mitigate the risks of maintaining legacy systems.
The upcoming launch of the AWS Asia Pacific (Malaysia) Region complements Astro’s ongoing broadcast transformation journey, which aims to further enable the deployment of innovative media and entertainment solutions. By capitalizing on the robust cloud infrastructure, unparalleled scalability, and advanced services provided by AWS, Astro aims to further improve enhanced in-country network infrastructure resiliency and performance, thus delivering enriched customer experiences.
Defining the Future of Broadcast
Broadcasters have traditionally managed their channel automation and playout systems within on-premises data centers. As Astro continues its expansion across multiple regions, the organization will see workflows being optimized, media operations enhanced, and playout system management streamlined. To further complement the company’s pursuit of these goals, Astro will implement Amagi’s flagship products on AWS: the Amagi CLOUDPORT channel playout platform and the Amagi MONITORING solution. These advanced solutions will support Astro’s commitment to operational excellence, offering enhanced resiliency and enabling quicker upgrades to service capabilities, thereby meeting the evolving needs of the broadcasting landscape.
Mauro Di Pietro Paolo, Chief Technology Officer at Astro said, “As Malaysia’s leading broadcaster, Astro continues to drive innovation, and our partnership with Amagi underscores our continuous dedication to pioneering advancements in the industry. At Astro, we needed a playout platform that would align with our vision for transformation in our broadcast and media operations, have in-built disaster recovery capabilities, and provide a modernization path for our end-of-life on-premises systems. We’ve selected Amagi because of their proven track record of deploying playout systems on AWS and have demonstrated their ability to be a transformational platform.”
Srinivasan KA, Co-Founder and Chief Revenue Officer at Amagi said, “We are delighted to partner with Astro, one of the most innovative and forward-looking media companies in Asia, to help them achieve their cloud transformation goals. By leveraging our cloud-native solutions built on AWS’s global infrastructure, we can provide Astro with a scalable, secure, and cost-effective playout platform to support their current and future needs. This collaboration also demonstrates our commitment to empowering media companies with cutting-edge cloud technology and best-in-class service.”
“The broadcast industry is rapidly changing, requiring broadcasters to stay competitive with increased agility, resiliency, cost efficiency, and unified workflows, which can be achieved with AWS cloud. AWS is proud to work with solutions providers like Amagi to drive the industry forward,” said Pete Murray, Country Manager at AWS. “We’re thrilled to see our long-term customer Astro continue its transformative journey to delight their customers, and with Amagi, we look forward to digitalizing and advancing the future of Malaysia’s media and entertainment industry.”
Amagi and Astro launched broadcast station playout origination on AWS for the first channels and disaster recovery services in May 2024. This marks the first large-scale, cloud-based playout solution by a broadcaster in Malaysia. To meet the ever-changing needs of these networks, Amagi will continue to work closely with Astro to scale and evolve its Amagi CLOUDPORT solution.
About Astro
Astro Malaysia Holdings Berhad (Astro) is Malaysia’s leading content and entertainment company, serving 5.3 million homes or 67% of Malaysian TV households, 8,400 enterprises, 18.2 million weekly listeners across FM radio and online, and 15.6 million visitors to our digital brands every month. We serve Malaysians with 3 distinct services – Astro Pay-TV, NJOI Prepaid and sooka, our own OTT for the millennials; and Astro Fibre, our own broadband service, offers greater value with its content-broadband bundles. Close to a million homes are already streaming the best of home entertainment via our Hybrid 4K UHD Ultra Box and HD Ulti Box, which can be self-installed and run on both satellite and broadband. Today, our customers enjoy streaming our local signatures, Astro Originals, live sports and the best global shows from Netflix, Disney+ Hotstar, HBO GO, iQIYI, TVBAnywhere+, beIN SPORTS CONNECT, BBC Player, Viu, ZEE5, WeTV, Qalbox by MuslimPro, and our own TV companion app Astro GO. Astro Radio, home to the country’s highest-rated radio brands across all key languages, and our digital brands including AWANI, SYOK, Gempak, Xuan and Astro Ulagam, connect Malaysians to content and stories that matter.
About Amagi
Amagi is a next-generation media technology company that provides cloud broadcast and targeted advertising solutions to broadcast TV and streaming TV platforms. Amagi enables content owners to launch, distribute, and monetize live linear channels on Free Ad-supported Streaming TV and video services platforms. Amagi also offers 24×7 cloud-managed services bringing simplicity, advanced automation, and transparency to the entire broadcast operations. Overall, Amagi supports 800+ content brands, 800+ playout chains, and over 3800+ channel deliveries on its platform in over 150 countries. Amagi has a presence in New York, Los Angeles, London, Paris, Melbourne, Seoul, Singapore, and broadcast operations in New Delhi, and innovation centers in Bangalore, Zagreb, and Lodz.
About Amazon Web Services
For over 15 years, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud platform. AWS offers over 200 fully-featured services for compute, storage, databases, networking, analytics, machine learning, and AI, Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 102 Availability Zones (AZs) within 32 geographic regions around the world.
In March 2023, AWS announced plans to launch an AWS Infrastructure Region in Malaysia in 2024. As part of its commitment to the region, AWS is planning to invest $6 billion (approx. MYR 25.5 billion) in Malaysia by 2037.
Amagi Contact: Aashish WashikarDirector – Corporate CommunicationsEmail: [email protected] : +91 9533390005
Photo: https://mma.prnewswire.com/media/2423741/Amagi_and_AWS.jpg
View original content:https://www.prnewswire.co.uk/news-releases/astro-malaysias-largest-broadcaster-selects-amagi-and-aws-to-transition-playout-services-to-the-cloud-302157075.html
Artificial Intelligence
The European Patent Office, The world’s most powerful permanent magnet: Japanese inventor selected as finalist for the European Inventor Award 2024
MUNICH, May 29, 2024 /PRNewswire/ — Magnets are all around us, they drive a wide array of modern technologies and exist in one way or another in almost every field on Earth. Permanent neodymium magnets are found nowadays in mobile phones, MRI scanners, electric vehicle motors, wind turbines and security systems as well as in jewellery, ABS brakes, pumps and generators. Their roles go from fastening boxes to helping generate electricity, guiding medical equipment and levitating components. The multifunctional benefits of magnets have changed the way our world works, and Sagawa’s neodymium magnets are a driving force behind the pervasive use of magnets worldwide. In recognition of his achievement, Sagawa is a finalist in the “Non-EPO Countries” category of the European Inventor Award 2024, having been selected by an independent jury from among 550 candidates for this year’s edition.
Motivated by the high price of cobalt at the time and inspired by the widespread availability and lower cost of iron, Sagawa set out in the late 70s and early 80s to find a replacement of cobalt-based magnet, but still be able to generate a robust, permanent magnetic field. He experimented with a wide variety of intermetallic compounds and phases before a breakthrough in the process led him to create the strong magnet. The process he developed is called sintering – a process that bonds the ground particles of his various magnetic components together using heat treatment. While magnets with similar compounds were being developed at the same time, this process made Sagawa’s magnet the strongest in the market.
Masato Sagawa is one of three finalists in the “Non-EPO Countries” category of the European Inventor Award 2024. The other finalists recognised for outstanding work are a Brazilian team led by Fernando Catalano and Micael Carmo for reducing noise and carbon emissions in air travel and American-based David Fattal for his advancements in display optics and software to create glasses-free 3D imaging. The EPO will announce the winners during a ceremony live-streamed here from Malta on 9 July 2024. In addition to each category, the EPO will reveal the Popular Prize winner, chosen by online public vote. Voting will remain open until the day of the ceremony.
Web: https://www.epo.org/en
View original content:https://www.prnewswire.co.uk/news-releases/the-european-patent-office-the-worlds-most-powerful-permanent-magnet-japanese-inventor-selected-as-finalist-for-the-european-inventor-award-2024-302156998.html
Artificial Intelligence
TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON’S DISEASE
– Treefrog will present two posters on their cell therapy program in Parkinson’s Disease and their proprietary encapsulation technology, C-Stem™ –
BORDEAUX, France, May 29, 2024 /PRNewswire/ — TreeFrog Therapeutics has a busy schedule at the ISCT’s 30th annual meeting, taking place in Vancouver, Canada this week, with two posters being presented, one of which has been awarded the Best Poster in the iPSC category. A poster on their transformational encapsulation technology, C-Stem™, will also be presented.
TreeFrog is a cell therapy company with a lead program in Parkinson’s disease, a complex neurodegenerative disease with no cure and treatments that offer symptomatic relief only. Decades of research demonstrate that cell therapy holds immense promise for Parkinson’s disease, with multiple clinical trials ongoing. However, the manufacturing of these cells must overcome major pharmaceutical challenges, including scalability, to be compatible with potential commercial phases. The cell therapy program at TreeFrog is based on C-Stem™, a proprietary technology platform that overcomes these challenges. In 2021, the company achieved a world-first of producing 15billion iPSCs in one run, in one week.
Michael Lanero Fidalgo, Chief Operating Officer, will represent the company for the Best Poster in the iPSC category, an award designed to recognize outstanding abstracts related to iPSC research. Poster #1219, First Off-The-Shelf Bioreactor Produced, iPSC-Derived Neural Microtissues Containing Dopaminergic Neurons Innervate the Striatum and Normalize Behavior in a Parkinson Rat Model, is also one of only twenty posters chosen for an elevator pitch presentation from the overall 600 considered.
Kevin Alessandri, co-founder and Chief Technology Officer, will present poster #1200 Cell encapsulation as a tool for stem cell-based cell therapy industrialization, a deep dive into how the C-Stem™ technology, can overcome the bottlenecks of the complex Chemistry, Manufacturing and Controls (CMC) in cell therapy. He will also participate as a KOL in the JSRM-ISCT iPSC workshop event iPSCs: From Bench to Bedside’ Scientific Signature Series.
Events:
Elevator Pitch presentation by Michael Lanero-Fidalgo, representing lead authors Nicolas Prudon & Lucia Cordero Espinoza May 29th, 2024 @ 12:00 – 13:00, Room 201iPSC Poster Presentation Networking reception (Posters #1219 & #1200) May 30th @ 18:00 – 19:30 Exhibit & Poster HalliPSC: Bench to Bedside: Scientific Signature Series, participation of Kevin Alessandri as KOL. June 1st, 2024 @ 7:30 – 16:00, Room 212-214www.treefrog.fr
CONTACT: Rachel MooneyChief Communications OfficerTreeFrog Therapeutics [email protected]
Logo – https://mma.prnewswire.com/media/2272329/treefrog_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/treefrog-therapeutics-picks-up-best-poster-award-at-the-international-society-for-cell–gene-therapy-isct-annual-meeting-for-their-cell-therapy-program-in-parkinsons-disease-302156935.html
-
Artificial Intelligence5 days ago
Titans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Artificial Intelligence5 days ago
Bybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Artificial Intelligence7 days ago
HONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Uncategorized5 days ago
GienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Uncategorized5 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence5 days ago
IoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence4 days ago
Overseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
-
Artificial Intelligence5 days ago
atNorth Wins ‘Colocation Provider of the Year’ and ‘Digital Infrastructure Project of the Year’ at Industry Award Events